Literature DB >> 24819345

Downregulation of connexin43 by microRNA-130a in cardiomyocytes results in cardiac arrhythmias.

Appledene Osbourne1, Tyler Calway1, Michael Broman1, Saoirse McSharry1, Judy Earley1, Gene H Kim2.   

Abstract

MicroRNAs (miRNAs) are now recognized as critical regulators of diverse physiological and pathological processes; however, studies of miRNAs and arrhythmogenesis remain sparse. Connexin43 (Cx43), a major cardiac gap junction protein, has elicited great interest in its role in arrhythmias. Additionally, Cx43 was a potential target for miR-130a as predicted by several computational algorithms. This study investigates the effect of miR-130a overexpression in the adult heart and its effect on cardiac rhythm. Using a cardiac-specific inducible system, transgenic mice demonstrated both atrial and ventricular arrhythmias. We performed ventricular-programmed electrical stimulation and found that the αMHC-miR130a mice developed sustained ventricular tachycardia beginning 6weeks after overexpression. Western blot analysis demonstrated a steady decline in Cx43 after 2weeks of overexpression with over a 90% reduction in Cx43 levels by 10weeks. Immunofluorescent staining confirmed a near complete loss of Cx43 throughout the heart. To validate Cx43 as a direct target of miR-130a, we performed in vitro target assays in 3T3 fibroblasts and HL-1 cardiomyocytes, both known to endogenously express miR-130a. Using a luciferase reporter fused to the 3'UTR of Cx43, we found a 52.9% reduction in luciferase activity in 3T3 cells (p<0.0001) and a 47.6% reduction in HL-1 cells (p=0.0056) compared to controls. Addition of an antisense miR-130a inhibitor resulted in a loss of inhibitory activity of the Cx43 3'UTR reporter. We have identified an unappreciated role for miR-130a as a direct regulator of Cx43. Overexpression of miR-130a may contribute importantly to gap junction remodeling and to the pathogenesis of atrial and ventricular arrhythmias.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atrial arrhythmia; Connexin43; MicroRNA; Ventricular arrhythmia

Mesh:

Substances:

Year:  2014        PMID: 24819345      PMCID: PMC4412372          DOI: 10.1016/j.yjmcc.2014.04.024

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  51 in total

1.  Remodeling of gap junctional channel function in epicardial border zone of healing canine infarcts.

Authors:  Jian-An Yao; Wajid Hussain; Pravina Patel; Nicholas S Peters; Penelope A Boyden; Andrew L Wit
Journal:  Circ Res       Date:  2003-01-30       Impact factor: 17.367

Review 2.  Structural and functional diversity of connexin genes in the mouse and human genome.

Authors:  Klaus Willecke; Jürgen Eiberger; Joachim Degen; Dominik Eckardt; Alessandro Romualdi; Martin Güldenagel; Urban Deutsch; Goran Söhl
Journal:  Biol Chem       Date:  2002-05       Impact factor: 3.915

3.  Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter.

Authors:  Atsushi Sanbe; James Gulick; Mark C Hanks; Qiangrong Liang; Hanna Osinska; Jeffrey Robbins
Journal:  Circ Res       Date:  2003-03-06       Impact factor: 17.367

4.  The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2.

Authors:  Baofeng Yang; Huixian Lin; Jiening Xiao; Yanjie Lu; Xiaobin Luo; Baoxin Li; Ying Zhang; Chaoqian Xu; Yunlong Bai; Huizhen Wang; Guohao Chen; Zhiguo Wang
Journal:  Nat Med       Date:  2007-04-01       Impact factor: 53.440

5.  Fibrosis of collagen I and remodeling of connexin 43 in atrial myocardium of patients with atrial fibrillation.

Authors:  Ming Hua Luo; Yu Shu Li; Ke Ping Yang
Journal:  Cardiology       Date:  2006-09-01       Impact factor: 1.869

6.  Focal gap junction uncoupling and spontaneous ventricular ectopy.

Authors:  David E Gutstein; Stephan B Danik; Steve Lewitton; David France; Fangyu Liu; Franklin L Chen; Jie Zhang; Newsha Ghodsi; Gregory E Morley; Glenn I Fishman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-05-13       Impact factor: 4.733

7.  Subdiaphragmatic murine electrophysiological studies: sequential determination of ventricular refractoriness and arrhythmia induction.

Authors:  David E Gutstein; Stephan B Danik; Jedd B Sereysky; Gregory E Morley; Glenn I Fishman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-15       Impact factor: 4.733

8.  MicroRNA-133 controls cardiac hypertrophy.

Authors:  Alessandra Carè; Daniele Catalucci; Federica Felicetti; Désirée Bonci; Antonio Addario; Paolo Gallo; Marie-Louise Bang; Patrizia Segnalini; Yusu Gu; Nancy D Dalton; Leonardo Elia; Michael V G Latronico; Morten Høydal; Camillo Autore; Matteo A Russo; Gerald W Dorn; Oyvind Ellingsen; Pilar Ruiz-Lozano; Kirk L Peterson; Carlo M Croce; Cesare Peschle; Gianluigi Condorelli
Journal:  Nat Med       Date:  2007-04-29       Impact factor: 53.440

Review 9.  Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation.

Authors:  Stanley Nattel; Ange Maguy; Sabrina Le Bouter; Yung-Hsin Yeh
Journal:  Physiol Rev       Date:  2007-04       Impact factor: 37.312

10.  MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure.

Authors:  Thomas Thum; Paolo Galuppo; Christian Wolf; Jan Fiedler; Susanne Kneitz; Linda W van Laake; Pieter A Doevendans; Christine L Mummery; Jürgen Borlak; Axel Haverich; Carina Gross; Stefan Engelhardt; Georg Ertl; Johann Bauersachs
Journal:  Circulation       Date:  2007-07-02       Impact factor: 29.690

View more
  29 in total

1.  Decreased expression of microRNA-130a correlates with TNF-α in the development of osteoarthritis.

Authors:  Zeng-Chun Li; Ning Han; Xin Li; Guang Li; Yang-Zhou Liu; Gui-Xin Sun; Yong Wang; Guo-Ting Chen; Guo-Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Increased HDAC3 and decreased miRNA-130a expression in PBMCs through recruitment HDAC3 in patients with spinal cord injuries.

Authors:  Yu-Dong Ma; Jing Fang; Hong Liu; Li Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A.

Authors:  Yuanqing Pan; Renjie Wang; Fengwa Zhang; Yonglin Chen; Qingfang Lv; Ge Long; Kehu Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 4.  Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications.

Authors:  Luc Leybaert; Paul D Lampe; Stefan Dhein; Brenda R Kwak; Peter Ferdinandy; Eric C Beyer; Dale W Laird; Christian C Naus; Colin R Green; Rainer Schulz
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

5.  MicroRNA-130a Regulation of Desmocollin 2 in a Novel Model of Arrhythmogenic Cardiomyopathy.

Authors:  Stefan R Mazurek; Tyler Calway; Cynthia Harmon; Priyanka Farrell; Gene H Kim
Journal:  Microrna       Date:  2017

6.  Role of microRNA-130a in myocardial hypoxia/reoxygenation injury.

Authors:  Hongyan Liu; Lei Huan; Jie Yin; Meiling Qin; Zengtang Zhang; Zhiqiang Zhang; Junye Zhang; Shu Wang
Journal:  Exp Ther Med       Date:  2016-12-19       Impact factor: 2.447

Review 7.  Differential expression of microRNAs in ischemic heart disease.

Authors:  Minwoo A Song; Alexandra N Paradis; Maresha S Gay; John Shin; Lubo Zhang
Journal:  Drug Discov Today       Date:  2014-10-23       Impact factor: 7.851

Review 8.  Genetic and epigenetic regulation of arrhythmogenic cardiomyopathy.

Authors:  Stefan Mazurek; Gene H Kim
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-04-25       Impact factor: 5.187

9.  DL-3-n-butylphthalide improves ventricular function, and prevents ventricular remodeling and arrhythmias in post-MI rats.

Authors:  Huiliang Qiu; Jin Ma; Huanlin Wu; Chunhua Ding
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-30       Impact factor: 3.000

Review 10.  Inhibitors of connexin and pannexin channels as potential therapeutics.

Authors:  Joost Willebrords; Michaël Maes; Sara Crespo Yanguas; Mathieu Vinken
Journal:  Pharmacol Ther       Date:  2017-07-15       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.